Insider Selling: DexCom, Inc. (DXCM) CEO Sells 12,000 Shares of Stock

DexCom, Inc. (NASDAQ:DXCM) CEO Kevin R. Sayer sold 12,000 shares of the firm’s stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $55.00, for a total value of $660,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Kevin R. Sayer also recently made the following trade(s):

  • On Wednesday, September 20th, Kevin R. Sayer sold 6,000 shares of DexCom stock. The stock was sold at an average price of $69.34, for a total value of $416,040.00.

Shares of DexCom, Inc. (DXCM) traded up $0.45 during trading on Tuesday, reaching $55.11. The company had a trading volume of 1,771,361 shares, compared to its average volume of 1,432,720. DexCom, Inc. has a 1-year low of $42.62 and a 1-year high of $88.80. The company has a debt-to-equity ratio of 0.84, a quick ratio of 5.50 and a current ratio of 5.86.

COPYRIGHT VIOLATION WARNING: “Insider Selling: DexCom, Inc. (DXCM) CEO Sells 12,000 Shares of Stock” was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.com-unik.info/2017/11/21/insider-selling-dexcom-inc-dxcm-ceo-sells-12000-shares-of-stock.html.

Several equities research analysts recently commented on the company. ValuEngine raised DexCom from a “sell” rating to a “hold” rating in a research note on Monday, November 6th. Morgan Stanley reduced their price objective on DexCom from $72.00 to $52.00 and set a “neutral” rating for the company in a research note on Friday, November 3rd. Barclays PLC reduced their price objective on DexCom from $60.00 to $57.00 and set an “equal weight” rating for the company in a research note on Thursday, November 2nd. Northland Securities reissued a “hold” rating and issued a $50.00 price objective on shares of DexCom in a research note on Thursday, November 2nd. Finally, TheStreet cut DexCom from a “c-” rating to a “d+” rating in a research note on Wednesday, October 25th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and fourteen have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $70.69.

Institutional investors have recently modified their holdings of the stock. Advisor Group Inc. lifted its holdings in DexCom by 104.9% during the second quarter. Advisor Group Inc. now owns 1,635 shares of the medical device company’s stock worth $119,000 after acquiring an additional 837 shares during the period. Zions Bancorporation lifted its holdings in DexCom by 36,222.2% during the third quarter. Zions Bancorporation now owns 3,269 shares of the medical device company’s stock worth $160,000 after acquiring an additional 3,260 shares during the period. IFP Advisors Inc lifted its holdings in DexCom by 30.5% during the second quarter. IFP Advisors Inc now owns 2,431 shares of the medical device company’s stock worth $178,000 after acquiring an additional 568 shares during the period. Toronto Dominion Bank lifted its holdings in DexCom by 251.0% during the third quarter. Toronto Dominion Bank now owns 3,647 shares of the medical device company’s stock worth $178,000 after acquiring an additional 2,608 shares during the period. Finally, Janney Montgomery Scott LLC lifted its holdings in DexCom by 9.2% during the second quarter. Janney Montgomery Scott LLC now owns 2,959 shares of the medical device company’s stock worth $216,000 after acquiring an additional 250 shares during the period.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Insider Buying and Selling by Quarter for DexCom (NASDAQ:DXCM)

What are top analysts saying about DexCom Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for DexCom Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit